GTHP - Guided Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1900
0.0000 (0.00%)
At close: 12:40PM EDT
Stock chart is not supported by your current browser
Previous Close0.1900
Open0.1900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1900 - 0.1900
52 Week Range0.0206 - 2.2400
Volume39
Avg. Volume7,064
Market Cap630,701
Beta (3Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-0.3260
Earnings DateNov 12, 2019 - Nov 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.00
Trade prices are not sourced from all markets
  • Business Wire

    Guided Therapeutics Reports New Progress with Chinese FDA and Increased Sales Forecast from Shandong Medical Device Technology Company

    Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced that it had received a new communication regarding regulatory approval of its LuViva line of products in China. According to the Company’s partner and distributor for China, Shandong Yaohuo Medical Device Technology Company, Ltd., the Chinese FDA will request a relatively small clinical trial in China of 60 to 120 patients, to be conducted at two hospitals. The study is expected to begin this summer and be completed within three months, after which Shandong will file final paperwork for approval.

  • Business Wire

    Guided Therapeutics Receives $2.5 Million Purchase Order from Chinese Partner Shandong Medical Device Technology Company

    Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced that it had received a purchase order in the amount of $2,538,070 from its Chinese co-manufacturing partner and distributor for China, Shandong Yaohuo Medical Device Technology Company, Ltd. Shandong has previously paid Guided Therapeutics nearly $1 million in license payments and invested upwards to another $1 million in infrastructure in China for the roll out of LuViva either later this year or early next year. The purchase order includes parts for final assembly of LuViva along with single use disposables that are consumed with each LuViva test. Approximately 25% of the purchase order will be paid upon Shandong’s filing with the Chinese FDA with the remainder due once Chinese FDA approval is obtained, which is expected within about one year.

  • Business Wire

    Guided Therapeutics Reports Significant Progress in Eliminating Variable Rate Convertible Loans and Restructuring Capitalization; Announces Reverse Stock Split

    Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, today announced it has successfully closed out variable rate convertible loans with three lenders and reached preliminary agreements with two other lenders to exchange their variable rate convertible notes for cash and fixed rate equity once a significant financing of the Company occurs. The Company has plans to reduce its debt to less than $3 million in the near future. In addition, the Company executed a 1:800 reverse stock split, effective March 29, 2019.